Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD38 monoclonal antibody SCTC21C

A monoclonal antibody that targets the cell surface glycoprotein CD38, with potential antineoplastic activity. Upon administration, anti-CD38 monoclonal antibody SCTC21C targets and binds to CD38 on CD38-positive tumor cells. This may kill, possiby through antibody-dependent cellular cytotoxicity (ADCC) or other responses, CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	SCTC 21C SCTC-21C SCTC21C

anti-CD38 monoclonal antibody SCTC21C

Search NCI's Drug Dictionary